Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Nystagmus, Pathologic × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Conditions

Breast Neoplasms 11735 Neoplasms 9361 Carcinoma, Non-Small-Cell Lung 6100 Prostatic Neoplasms 5640 Colorectal Neoplasms 5275 Lung Neoplasms 4518 Multiple Myeloma 3186 Pancreatic Neoplasms 3174 Neoplasm Metastasis 3120 Leukemia, Myeloid, Acute 3104 Carcinoma, Hepatocellular 2907 Ovarian Neoplasms 2832 Melanoma 2805 Stomach Neoplasms 2722 Lymphoma 2681 Head and Neck Neoplasms 2313 Recurrence 2268 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2207 Leukemia 2131 Brain Neoplasms 2099 Colonic Neoplasms 2065 Lymphoma, Non-Hodgkin 2019 Rectal Neoplasms 1955 Uterine Cervical Neoplasms 1910 Glioblastoma 1813 Leukemia, Lymphocytic, Chronic, B-Cell 1776 Carcinoma, Renal Cell 1700 Squamous Cell Carcinoma of Head and Neck 1651 Lymphoma, Follicular 1631 Esophageal Neoplasms 1603

Interventions

Amifampridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02189720 2025-03-26

EAP-001

Catalyst Pharmaceuticals, Inc.

Approved for marketing

Nystagmus, Pathologic, Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

Data powered by HemOnc (CC BY 4.0) Colophon ⚡